ZURICH, April 29 (Reuters) - Novartis AG said a study shows that 80-83 percent of patients taking its multiple sclerosis drug FTY720 are relapse-free compared to 69 percent of those on the leading current treatment.
ZURICH, April 29 (Reuters) - Novartis AG said a study shows that 80-83 percent of patients taking its multiple sclerosis drug FTY720 are relapse-free compared to 69 percent of those on the leading current treatment.
